Non Small Cell Lung Cancer (NSCLC) Global Drugs Market Forecast To Grow $26.71 Billion In 2025 At CAGR of 15.7%

This is a professional and depth research report 2016 on Non-Small Cell Lung Cancer (NSCLC) – Global Drug Forecast and Market Analysis to 2025 that would help to know the world’s major regional market conditions of Non-Small Cell Lung Cancer (NSCLC) – Global Drug Market in the main region. The NSCLC therapeutics market is expected to grow at a positive CAGR of 15.7%, reaching $ 26.71 Billion in the 8MM by 2025. The growth of the NSCLC market during the forecast period will be driven partly by increasing incident cases of NSCLC in the US, 5EU, Japan, and China, as the population ages.

Complete Report with 608 pages and 209 Tables Including 85 Figures Is Available at:

http://www.reportsnreports.com/reports/855298-pharmapoint-non-small-cell-lung-cancer-nsclc-global-drug-forecast-and-market-analysis-to-2025.html

 

Key Companies Analysed:

Eli Lilly, Pfizer, AZ, BMS, Merck & Co, Novartis, BI

Key Questions Answered:

Based on interviews with key opinion leaders (KOLs), GlobalData has identified the major unmet needs in the NSCLC marketplace. Will the leading pipeline agents fulfil these unmet needs during the forecast period (2015-2025)?

What research and development (R&D) strategies will companies leverage to compete in the future NSCLC marketplace?

Which pipeline products are poised to make a major clinical and commercial impact?

What clinical and commercial factors are likely to influence NSCLC drug uptake in the 8MM?

Request Sample Report At: http://www.reportsnreports.com/contacts/discount.aspx?name=855298

Key Findings:

The increasing incorporation of premium-priced immune checkpoint inhibitor immunotherapies into the NSCLC treatment algorithm, particularly in the first-line setting, will be one major driver. Collectively, immunotherapies will reach $17.5B in sales by 2025, accounting for roughly 65% of total sales in the NSCLC market. Of the $17.5B total, Keytruda, Opdivo, and Tecentriq are projected to contribute $5.2B, $5.5B, and $2.8B, respectively. The increasing incidence of NSCLC in the 8MM will also drive growth. China, in particular, will see its NSCLC incident cases increase dramatically over the forecast period, at an Annual Growth Rate (AGR) of 4.7%. Overall, across the 8MM, the incidence of NSCLC is expected to increase at an AGR of 3.1% from 2015-2025. This increase, coupled with an anticipated increase in branded therapy prescriptions in China, will drive the growth of both the Chinese and global NSCLC markets over the forecast period.

Patent expiration of several blockbuster drugs, including Tarceva and Alimta, and the uptake of generics will limit growth. GlobalData expects sales of the patented drug in the 8MM to decrease from $783M in 2015 to $18M by 2025. In addition, sales of Alimta will decrease from $2.1B in 2015 to $54M in 2025.An increasing emphasis on cost-consciousness is anticipated over the forecast period, which will limit premium pricing opportunities for developers of NSCLC pipeline agents. GlobalData expects this era of austerity and healthcare reform to make it increasingly more difficult for pharmaceutical companies to gain reimbursement approval for their new NSCLC therapies.

Get This Report: http://www.reportsnreports.com/purchase.aspx?name=855298

Key Highlights:

Overview of NSCLC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options. Topline NSCLC drug market revenue from 2015-2025, annual cost of therapy (ACOT), and major product sales in 17 patient segments during the forecast period are included. Key topics covered include strategic competitor assessment, market characterization, unmet needs, opportunities, R&D strategies, and clinical trial mapping for the NSCLC market.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products. Analysis of the current and future market competition in the global NSCLC market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the global NSCLC therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the NSCLC market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

About Us:

Reportsnreports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

 

 

%d bloggers like this: